Page last updated: 2024-11-05

4,4'-bipyridyl

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4,4'-Bipyridyl (also known as bipyridine) is a heterocyclic organic compound with the formula (C5H4N)2. It is a white solid that is soluble in organic solvents. 4,4'-Bipyridyl is a common ligand in coordination chemistry, forming complexes with a wide range of metal ions. It is also used as a building block in the synthesis of polymers, and as a catalyst in organic reactions. 4,4'-Bipyridyl is of particular interest to researchers because of its ability to form stable complexes with metal ions, its luminescent properties, and its potential applications in various fields such as electronics, materials science, and biomedicine.'

4,4'-bipyridine : A bipyridine in which the two pyridine moieties are linked by a bond between positions C-4 and C-4'. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID11107
CHEMBL ID1374568
CHEBI ID30985
SCHEMBL ID9728
MeSH IDM0105821

Synonyms (86)

Synonym
EU-0068109
AC-7555
CBDIVE_014486
BB 0219905
brn 0113176
nsc 404423
ccris 2363
ai3-00138
einecs 209-036-3
CHEBI:30985 ,
4,4'-bpy
4,4-bipyridin
gamma,gamma'-dipyridyl
gamma,gamma'-bipyridyl
IDI1_017636
553-26-4
4,4'-bipyridine
inchi=1/c10h8n2/c1-5-11-6-2-9(1)10-3-7-12-8-4-10/h1-8
nsc404423
4,4'-dipyridine
nsc-404423
4,4'-dipyridyl hydrate
4,4-dipyridyl
4-(4-pyridyl)pyridine
4,4-bipyridyl
.gamma.,.gamma.'-bipyridyl
4,4'-bipyridyl ,
4,4'-dipyridyl
.gamma.,.gamma.'-dipyridyl
MLS000702205 ,
smr000224611
4,4'-dipyridyl, 98%
NCGC00163975-01
MAYBRIDGE3_006249
SR-01000400279-2
D-7300
D-7304
HMS1448M01
B0469
AKOS000528630
4-pyridin-4-ylpyridine
STK868236
A8015
4,4'-bipyridine;4,4'-dipyridyl
NCGC00163975-03
NCGC00163975-02
HMS2529I24
4-pyridin-4-ylpyridin
4, 4'-dipyridine
tox21_201668
dtxsid2027200 ,
NCGC00254394-01
cas-553-26-4
dtxcid107200
tox21_300577
NCGC00259217-01
CCG-44317
37275-48-2
dopamine nmethyltransferase
methyltransferase, dopamine n-
CHEMBL1374568
x4o2od61cb ,
5-23-08-00028 (beilstein handbook reference)
unii-x4o2od61cb
FT-0602807
AM81315
SCHEMBL9728
4,4' bipyridine
4,4'-di-pyridine
.gamma.,.gamma.'-dipyridyl [mi]
4,4-bipyridine
bipyridine, 4,4'-
OPERA_ID_1063
mfcd00006416
J-004914
4-(pyridin-4-yl)pyridine
F0900-3898
SR-01000400279-1
sr-01000400279
4,4'-bipyridyl, anhydrous, pestanal(r), analytical standard
Q229839
CS-W018005
AS-11016
4,4'-dipyridyl-d8
EN300-18088
Z57160158

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The single oral LD50 for 4,4'-dipyridyl was 175 mg/kg in male and 172 mg/kg in female rats; for 2,2'-dipyridyl it was 100 and 107 mg/kg, respectively."( Acute and subacute toxicity in Sherman strain rats exposed to 4,4'- and 2,2'-dipyridyl.
Groce, DF; Kimbrough, RD, 1982
)
0.26

Dosage Studied

ExcerptRelevanceReference
" Equivalent compounds lacking the heteroatom, when given in the same dosing regimen (75 mg/kg, ig, daily for 3 days), did not induce this or any other drug-metabolizing enzyme activity."( Concomitant induction of microsomal epoxide hydrolase and UDP-glucuronosyltransferase activities by dipyridine compounds.
Franklin, MR; Moody, DE,
)
0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
bipyridine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (20)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency0.00220.006038.004119,952.5996AID1159521
ATAD5 protein, partialHomo sapiens (human)Potency11.58210.004110.890331.5287AID504467
TDP1 proteinHomo sapiens (human)Potency13.34130.000811.382244.6684AID686978; AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency7.94330.180013.557439.8107AID1460
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency31.54560.001022.650876.6163AID1224838; AID1224893
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency24.33650.003041.611522,387.1992AID1159552
retinoid X nuclear receptor alphaHomo sapiens (human)Potency28.95070.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency39.98820.001530.607315,848.9004AID1224841; AID1259401
estrogen nuclear receptor alphaHomo sapiens (human)Potency49.06780.000229.305416,493.5996AID1259244; AID1259248; AID743069; AID743080; AID743091
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency35.48130.001024.504861.6448AID588534
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency54.94100.023723.228263.5986AID743223
aryl hydrocarbon receptorHomo sapiens (human)Potency62.94170.000723.06741,258.9301AID743085; AID743122
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency54.941019.739145.978464.9432AID1159509
chromobox protein homolog 1Homo sapiens (human)Potency89.12510.006026.168889.1251AID540317
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency37.00180.000627.21521,122.0200AID651741; AID743202; AID743219
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency79.43280.050127.073689.1251AID588590
gemininHomo sapiens (human)Potency0.51740.004611.374133.4983AID624297
lamin isoform A-delta10Homo sapiens (human)Potency0.05620.891312.067628.1838AID1487
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency48.95300.001557.789015,848.9004AID1259244
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency48.95300.001551.739315,848.9004AID1259244
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (27)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID687183Inhibition of human recombinant N-terminal His-tagged IDO1 (Ala2 to Gly403) overexpressed in Escherichia coli BL21 at 1 mM at pH 6.5 after 60 mins by HPLC analysis2012Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
Rational design of 4-aryl-1,2,3-triazoles for indoleamine 2,3-dioxygenase 1 inhibition.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (134)

TimeframeStudies, This Drug (%)All Drugs %
pre-19908 (5.97)18.7374
1990's8 (5.97)18.2507
2000's24 (17.91)29.6817
2010's85 (63.43)24.3611
2020's9 (6.72)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 44.61

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index44.61 (24.57)
Research Supply Index4.92 (2.92)
Research Growth Index5.15 (4.65)
Search Engine Demand Index65.09 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (44.61)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (0.74%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other135 (99.26%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]